PCRX Pacira BioSciences, Inc.
Price Chart
Executive Summary
Pacira BioSciences issued a press release defending its intellectual property strategy against activist investor DOMA Perpetual Capital Management ahead of the 2026 annual meeting. The filing rebuts DOMA's claims about patent weakness, highlights the Fresenius Kabi settlement providing EXPAREL exclusivity through early 2030, and urges stockholders to vote for management's three board nominees on the BLUE proxy card.
Actionable Insight
The proxy fight outcome is binary: management slate victory maintains current strategy and IP narrative; DOMA board seats could shift capital allocation and IP litigation approach. Vote outcome likely within weeks. Monitor for institutional proxy advisor recommendations (ISS/Glass Lewis) which will be decisive given activist holds <10% likely.
Key Facts
- Activist DOMA Perpetual Capital Management has nominated three director candidates for Pacira's 2026 annual meeting
- Pacira's Fresenius Kabi settlement provides full EXPAREL exclusivity through early 2030 with gradual capped market entry until 2039
- Pacira has 21 Orange Book-listed patents across two families, with the newer IVRA family (940 patent) providing protection into July 2044
- Two recent Paragraph IV generic challenges have been filed, but Pacira notes these are early-stage ANDA filings without proven bioequivalence
- Goldman Sachs is acting as financial advisor and Perkins Coie as legal counsel to Pacira
Financial Impact
No specific financial figures provided; EXPAREL exclusivity runway through 2030 is the key commercial value driver
Risk Factors
- Activist wins board seats, potentially altering IP litigation strategy or pushing for sale
- Generic challenges to EXPAREL succeed despite Pacira's patent defense, eroding revenue base
- Patent litigation outcomes remain uncertain; IVRA family patents untested in court
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001628280-26-038111 |
| Document: 0001628280-26-038111-index-headers.html | 0001628280-26-038111 |
| Document: 0001628280-26-038111-index.html | 0001628280-26-038111 |
| Document: 0001628280-26-038111.txt | 0001628280-26-038111 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 13, 2026
2d ago
|
Insider Cluster
| — | awaiting T+1 | — | — |
|
Jun 4, 2026
10d ago
|
DEFA14A
| $22.67 awaiting T+1 | awaiting T+1 | — | $22.99 (+1.41%) |
|
Jun 4, 2026
10d ago
|
144
| $22.67 $22.75 | ▲ +0.35% | ▲ +2.95% | $22.99 (+1.41%) |
|
Jun 1, 2026
13d ago
|
DEFA14A
| $22.25 $22.32 | ▲ +0.31% | ▲ +1.04% | $22.99 (+3.33%) |
|
May 27, 2026
18d ago
|
DEFA14A
| $23.68 $23.22 | ▼ −1.94% | ▼ −2.18% | $22.99 (−2.91%) |
|
May 26, 2026
19d ago
|
DEFA14A
| $24.04 $23.68 | ▼ −1.50% | ▼ −2.05% | $22.99 (−4.37%) |
|
May 20, 2026
25d ago
|
DEFA14A
| $23.48 $23.35 | ▼ −0.55% | ▼ −1.00% | $22.99 (−2.09%) |
|
May 20, 2026
25d ago
|
Press Release
| $23.00 $23.48 | ▲ +2.09% | ▲ +1.89% | $22.99 (−0.04%) |
|
Apr 30, 2026
6w ago
|
8-K
| $24.44 $24.69 | ▲ +1.02% | ▲ +1.36% | $22.99 (−5.93%) |
|
Apr 17, 2026
8w ago
|
PREC14A
| $24.90 $24.64 | ▼ −1.04% | ▼ −0.39% | $22.99 (−7.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access